Melinta Therapeutics

OverviewSuggest Edit

Melinta Therapeutics is an antibiotics-focused company that develops and commercializes antibiotics to overcome drug-resistant infections. Its four marketed products include Baxdela (delafloxacin), Vabomere (meropenem and vaborbactam), Orbactiv (oritavancin), and Minocin (minocycline) for injection. The Company also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market.

Employee Ratings2.4

Latest Updates

Employees (est.) (Sept 2020)146
Share Price (May 2020)$0.1
Cybersecurity ratingAMore

Key People/Management at Melinta Therapeutics

Jennifer Sanfilippo

Jennifer Sanfilippo

Interim Chief Executive Officer and Director
David Gill

David Gill

Chairman of the Board
Peter Milligan

Peter Milligan

Bruce L. Downey

Bruce L. Downey

Jay Galeota

Jay Galeota

Aron Schwartz

Aron Schwartz

Show more

Melinta Therapeutics Office Locations

Melinta Therapeutics has an office in New Haven
New Haven, US
300 George Street Suite 301
Show all (1)

Melinta Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Melinta Therapeutics total Funding

$519.2 m

Melinta Therapeutics latest funding size

$123.20 m

Time since last funding

2 years ago

Melinta Therapeutics investors

Melinta Therapeutics's latest funding round in May 2018 was reported to be $123.2 m. In total, Melinta Therapeutics has raised $519.2 m
Show all financial metrics

Melinta Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Melinta Therapeutics Online and Social Media Presence

Embed Graph

Melinta Therapeutics News and Updates

Melinta Therapeutics stock slides after company files for chapter 11 bankruptcy protection

Shares of biotech Melinta Therapeutics Inc. slid 59% Friday, after the developer of novel antibiotics to treat bacterial infections filed for chapter 11 bankruptcy protection. Morrison, New Jersey-based Melinta said it has reached a restructuring agreement with the lenders under its senior credit f…

Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility

Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations

Melinta Therapeutics stock plunges toward record low after another 'going concern' warning

Shares of Melinta Therapeutics Inc. plummeted 45% toward a record low to pace all premarket decliners Wednesday, after the commercial-stage drug maker included a "going concern" warning in its quarterly filing, for the third consecutive quarter. The first warning by the company that it believed the…

Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting

~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~

Thinking about buying stock in Beyond Meat, DGSE, Interpace Diagnostics, Melinta Therapeutics, or Oracle?

NEW YORK, June 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BYND, DGSE, IDXG, MLNT, and ORCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia

~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~
Show more

Melinta Therapeutics Frequently Asked Questions

  • When was Melinta Therapeutics founded?

    Melinta Therapeutics was founded in 2000.

  • Who are Melinta Therapeutics key executives?

    Melinta Therapeutics's key executives are Jennifer Sanfilippo, David Gill and Peter Milligan.

  • How many employees does Melinta Therapeutics have?

    Melinta Therapeutics has 146 employees.

  • Who are Melinta Therapeutics competitors?

    Competitors of Melinta Therapeutics include Retrophin, Palatin Technologies and GBT (Global Blood Therapeutics).

  • Where are Melinta Therapeutics offices?

    Melinta Therapeutics has an office in New Haven.

  • How many offices does Melinta Therapeutics have?

    Melinta Therapeutics has 1 office.